SCHEMBL3964590

SCHEMBL3964590

CNC(=O)N1CCCC(C2(Cc3cccc(Cl)c3)C(=O)Nc3cc(Cl)ccc32)C1

nearest known ligand 0.82

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 11/20 0.82
TP53 P04637 7/20 0.82
CRBN Q96SW2 1/20 0.38
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
GHSR Q92847 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
KDM4E B2RXH2 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966847 0.92 MDM2 (0.81) MDM2TP53KDM4E
SCHEMBL3968122 0.92 MDM2 (0.80) MDM2TP53GHSR
SCHEMBL3970646 0.91 MDM2 (0.79) MDM2TP53GHSR
SCHEMBL3971402 0.90 MDM2 (1.00) MDM2TP53KDM4E
SCHEMBL3964720 0.90 MDM2 (0.86) MDM2TP53CHRM2CHRM3
SCHEMBL3967696 0.90 MDM2 (0.77) MDM2TP53KDM4ECHRM2CHRM3
SCHEMBL8249405 0.90 TP53 (0.77) MDM2TP53KDM4E
SCHEMBL8249668 0.90 MDM2 (0.77) MDM2TP53KDM4E
SCHEMBL3964717 0.89 MDM2 (0.68) MDM2TP53CRBNGHSR
SCHEMBL8251713 0.89 MDM2 (0.79) MDM2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US claimed
JP-2008543917-A 2008-12-04 JP claimed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP claimed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO claimed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US claimed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 MDM2 759/4885TP53 96/4885CRBN 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.